.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
CRASH-2 was a large randomised placebo-controlled trial assessing early tranexamic acid in adult trauma patients with, or at risk of, significant bleeding. More than 20,000 patients from 274 hospitals in 40 countries were randomised within eight hours of injury to tranexamic acid or placebo. The study established that an antifibrinolytic treatment can influence survival after traumatic haemorrhage, with the greatest benefit associated with early administration. The trial also found no major excess of vascular occlusive events attributable to tranexamic acid. For clinicians, timing is central. Tranexamic acid is most useful when given early in patients who are bleeding or at substantial risk of bleeding, alongside definitive haemorrhage control and blood-component resuscitation. It is not a substitute for surgery, interventional radiology or correction of shock. The trial directly supports CritiCARE's focus on trauma-related coagulopathy and haemorrhage control. It is also a good example of how a simple, inexpensive intervention can have global relevance when delivered promptly. The practical takeaway is to incorporate tranexamic acid into an established trauma haemorrhage pathway rather than treating it as an isolated medication decision.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
CRASH-2 was a large randomised placebo-controlled trial assessing early tranexamic acid in adult trauma patients with, or at risk of, significant bleeding. More than 20,000 patients from 274 hospitals in 40 countries were randomised within eight hours of injury to tranexamic acid or placebo. The study established that an antifibrinolytic treatment can influence survival after traumatic haemorrhage, with the greatest benefit associated with early administration. The trial also found no major excess of vascular occlusive events attributable to tranexamic acid. For clinicians, timing is central. Tranexamic acid is most useful when given early in patients who are bleeding or at substantial risk of bleeding, alongside definitive haemorrhage control and blood-component resuscitation. It is not a substitute for surgery, interventional radiology or correction of shock. The trial directly supports CritiCARE's focus on trauma-related coagulopathy and haemorrhage control. It is also a good example of how a simple, inexpensive intervention can have global relevance when delivered promptly. The practical takeaway is to incorporate tranexamic acid into an established trauma haemorrhage pathway rather than treating it as an isolated medication decision.
4 weeks back
A bioengineered oral nanozyme microsupplement converts pathological ROS into a protective polydopamine hydrogel shield. By curbing neutrophil extracellular traps and balancing T cells, this platform outperforms standard 5-ASA in preclinical colitis models, opening new paths for sustained remission.
3 days back
Recent research reveals that downregulating YAP1/TAZ-TEAD via Hippo signaling triggers spontaneous human trophoblast syncytialization in 3D cultures, illuminating placental biology and preeclampsia.
4 weeks back
Abdominal aortic aneurysm rupture remains a catastrophic vascular emergency. Groundbreaking research reveals that USP53 accelerates aneurysm progression by reprogramming smooth muscle cell metabolism toward aerobic glycolysis, highlighting a promising target beyond conventional diameter-based surveillance.
4 days back
A breakthrough study leverages natural language processing to accurately identify incident medication-related osteonecrosis of the jaw and track antiresorptive drug holidays from clinical narratives in electronic health records, advancing osteoporosis pharmacovigilance and dental safety.
3 days back
Recent research defines ferro-aging as a conserved iron-lipid axis driving organ decline across primates. Age-related iron dyshomeostasis stimulates ACSL4-mediated lipid peroxidation, promoting cellular senescence. Notably, vitamin C directly inhibits ACSL4, suppressing phospholipid oxidation and multi-organ decay.
4 days back
